id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-2374-0006,FDA,FDA-2016-E-2374,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-07-29T04:00:00Z,2018,7,2018-07-29T04:00:00Z,,2018-07-29T06:05:48Z,,0,0,090000648357ae9a
FDA-2016-E-2374-0005,FDA,FDA-2016-E-2374,Determination of Regulatory Review Period for Purposes of Patent  Extension; YONDELIS,Notice,Determinations,2017-11-28T05:00:00Z,2017,11,2017-11-28T05:00:00Z,2018-01-30T04:59:59Z,2017-11-28T15:55:11Z,2017-25683,0,0,0900006482cb669e
FDA-2016-E-2374-0004,FDA,FDA-2016-E-2374,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-08-21T04:00:00Z,2017,8,2017-08-21T04:00:00Z,,2017-08-21T16:34:27Z,,0,0,0900006482a8c5cd
FDA-2016-E-2374-0003,FDA,FDA-2016-E-2374,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-26T04:00:00Z,2016,8,2016-08-26T04:00:00Z,,2016-08-26T15:39:43Z,,0,0,09000064821a0963
FDA-2016-E-2374-0001,FDA,FDA-2016-E-2374,"Patent Extension Application from King & Spaulding LLP (on behalf of Pharma Mar, S.A.)",Other,Application,2016-08-02T04:00:00Z,2016,8,2016-08-02T04:00:00Z,,2016-08-02T17:07:59Z,,0,0,090000648214db58
FDA-2016-E-2374-0002,FDA,FDA-2016-E-2374,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-08-02T04:00:00Z,2016,8,2016-08-02T04:00:00Z,,2016-08-02T17:08:30Z,,0,0,090000648214db5a